还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

* x5 K, \4 |: b  B5 L' t' W# L                               
登录/注册后可看大图

* E; j- K# }2 Z请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

, P8 Q' L' P$ W  H6 C可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
" ]: `) |- t/ r: L& |) D

Sub-category:
Molecular Targets
& A; l+ z/ W! l( Q2 F# N7 z
: Z( J2 \- U4 u
Category:
Tumor Biology


Meeting:
9 c$ q$ c7 ?4 f2011 ASCO Annual Meeting
* d4 c) G* @. q! R& \

Session Type and Session Title:
. i- f+ n( O& z- H* T, dPoster Discussion Session, Tumor Biology


Abstract No:
10517

3 c: q3 k, [$ O/ H" _
4 a; G0 K0 ?" _( m  wCitation:
. k5 F$ K0 G6 uJ Clin Oncol 29: 2011 (suppl; abstr 10517)
; F% T, z8 `- n( O
! A# b% {0 R& `, q3 N* J
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
0 _2 L6 a7 H$ G0 U


* w9 Z# f: o( ~; S6 Y0 R7 Z, f5 D, IAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

# a: }1 P5 o6 z! CAbstract:

. H4 Y7 O! \: t# D3 A1 h
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 w5 W+ E; [5 ?: S3 x4 \/ q

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

: e1 Z& X, e- j0 `                               
登录/注册后可看大图

- M' t. Z' d7 Z* r没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

4 `# z+ |# o; b8 @4 Z化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

9 |( W0 S) @3 M! d% _1 z/ w8 Q                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

/ F# x! j- ~) ?7 _/ w! g. M平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

  u+ i4 z& Y! u2 B5 k$ |3 q! f1 s现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊